Skip to main content
. Author manuscript; available in PMC: 2013 Jan 28.
Published in final edited form as: Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Dec;114(6):764–770. doi: 10.1016/j.oooo.2012.08.444

Table I.

Demographic and clinicopathologic features of study patients

Patient Age/sex/race Disease, site BP route, dose, duration Reason for BP use
1 80/F/W ONJ stage I, left posterior mandible Alendronate orally, 70 mg/wk, 12 mo Osteoporosis
2 75/M/W ONJ stage II, left posterior mandible Zoledronic acid IV, 4 mg/mo, 18 mo Prostate cancer
3 80/F/W ONJ stage I, right posterior mandible Alendronate orally, 70 mg/wk, 12 mo Osteoporosis
4 74/M/W ONJ stage II, left posterior mandible Zoledronic acid IV, 4 mg/mo, 36 mo Prostate cancer
5 75/F/W ONJ stage III, right posterior mandible Alendronate orally, 70 mg/wk, 36 mo Osteoporosis
6 81/F/W Non-ONJ control Alendronate orally, 70 mg/wk, 12 mo Osteoporosis
7 77/M/W Non-ONJ control Zoledronic acid IV, 4 mg/mo, 16 mo Prostate cancer
8 82/F/W Non-ONJ control Alendronate orally, 70 mg/wk, 13 mo Osteoporosis
9 71/M/W Non-ONJ control Zoledronic acid IV, 4 mg/mo, 35 mo Prostate cancer
10 76/F/W Non-ONJ control Alendronate orally, 70 mg/wk, 38 mo Osteoporosis